Rick Doblin
Founder and President of MAPS
Key Impact
The central figure in the global advocacy and regulatory maturation of MDMA-assisted therapy.
Background & Research
Rick Doblin is the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). For over three decades, he has led efforts to establish psychedelics as prescription medicines, focusing on the FDA approval of MDMA for PTSD. His work bridges public policy, clinical science, and advocacy, aiming to create a legal and safe context for the beneficial use of psychedelics for healing and growth.
Collaboration Network
35 collaborators· click a node to visit their profile
Full network →Compounds
Topics
PTSDSafety & Risk ManagementAnxiety DisordersDepressive DisordersSubstance Use Disorders (SUD)Interpersonal Functioning & Social ConnectednessSuicidalitySet & SettingAdolescentsVeteransPersonality & Trait FactorsPalliative & End-of-Life DistressNeurocognitive DisordersNeuroimaging & Brain MeasuresAutism Spectrum Disorder (ASD)CreativityEquity and EthicsPublic Health, Prevention & Behaviour ChangeEating DisordersMajor Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)Health Economics & ReimbursementAlcohol Use Disorder (AUD)